Anetumab corixetan is under clinical development by Bayer and currently in Phase I for Metastatic Adenocarcinoma of The Pancreas. According to GlobalData, Phase I drugs for Metastatic Adenocarcinoma of The Pancreas have an 88% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Anetumab corixetan’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Anetumab corixetan overview
Anetumab Corixetan is under development for the treatment of malignant mesothelioma, metastatic pancreatic adenocarcinoma and serous ovarian cancer. The drug candidate is a thorium-227 labeled antibody-chelator conjugate, which is administered through intravenous route. It acts by targeting mesothelin expressing cancers. The drug candidate is developed based on HuCAL (human combinatorial antibody library) technology.
It was also under development treatment for lung cancer and bone metastasis.
Bayer is engaged in the discovery, development, manufacturing, and commercialization of products for human health, and agriculture. It provides medicines for cardiovascular diseases, women’s health, cancer, hematology, ophthalmology and other indications. It also strives to develop new molecules and technologies for use in the fields of medicine and modern agriculture. The company’s product portfolio includes prescription products, specialty pharmaceuticals, diagnostic imaging equipment, non-prescription (over the counter or OTC) products, seeds, crop protection solutions and non-agricultural pest control solutions. Bayer markets its healthcare and crop protection products essentially through wholesalers, pharmacies, hospitals and retailers. It operates through a network of subsidiaries in Asia-Pacific, Europe, North America, Latin America, Africa and the Middle East. Bayer is headquartered in Leverkusen, North Rhine-Westphalia, Germany.
For a complete picture of Anetumab corixetan’s drug-specific PTSR and LoA scores, buy the report here.